

Amendments to the Claims:

Please cancel claims 1-6, 8-10, and 12; please amend claims 7, 13-14, and 16 as summarized below.

Claim 1. (canceled)

Claim 2. (canceled)

Claim 3. (canceled)

Claim 4. (canceled)

Claim 5. (canceled)

Claim 6. (canceled)

Claim ~~1~~¹ (amended) A FLINT analog resistant to proteolysis at position 218 of SEQ ID NO:1 comprising ~~an amino acid substitution in~~^{the protein of} SEQ ID NO:1, ~~selected from the group~~^{with the exception that the residue of} position 218 ~~consisting of:~~^{is a substitution}

- a. Arg at position 218 is replaced by Gln
- b. Arg at position 218 is replaced by Glu;
- ~~c. Thr at position 216 is replaced by Pro;~~
- ~~c~~ ~~d~~. Arg at position 218 is replaced by Ala;
- ~~d~~ ~~e~~. Arg at position 218 is replaced by Gly;
- ~~e~~ ~~f~~. Arg at position 218 is replaced by Ser;
- ~~f~~ ~~g~~. Arg at position 218 is replaced by Val;
- ~~g~~ ~~h~~. Arg at position 218 is replaced by Tyr; and
- ~~h~~ ~~i~~. Arg at position 218 is replaced by Asn; and
- ~~i~~ ~~j~~. ~~Pro at position 217 is replaced by Tyr.~~

Claim 8. (canceled)

Claim 9. (canceled)

Claim 10. (canceled)

Claim 11. (canceled)

Claim 12. (canceled)

Claim ~~13~~² (amended) A FLINT analog ~~as in Claim 1~~ wherein Thr at position 216 of SEQ ID NO:1 is replaced by Pro, and Arg at position 218 is replaced by Gln.

Claim ~~14~~³ (amended) A method to treat or prevent a disease or condition in a mammal comprising the administration of a therapeutically effective amount of a protease resistant FLINT analog of claim ~~2~~¹ or claim ~~13~~².

Serial No. 09/936,019

Reply to Office Action of Dec. 18, 2003

Claim ~~15~~⁴ (original) A method as in Claim ~~14~~³ wherein said disease or condition is acute lung injury, acute respiratory distress syndrome, or ulcerative colitis.

Claim ~~16~~⁵ (amended) A pharmaceutical formulation comprising as an active ingredient a protease resistant FLINT analog of claim ~~2~~¹ or claim ~~13~~² associated with one or more pharmaceutically acceptable carriers, excipients, or diluents thereof.

Claim 17-20 (canceled).

Claim ~~21~~⁶ (original) A FLINT analog resistant to proteolysis at position 218 of SEQ ID NO:1 comprising the amino acid sequence of SEQ ID NO:1, wherein Arg at position 218 is substituted by Gln.

Claims 22-23 (canceled)